A Study to Evaluate U3-1402 in Subjects With Advanced or Metastatic Colorectal Cancer
Study Details
Study Description
Brief Summary
This study is designed to primarily evaluate the safety and efficacy of U3-1402 in participants with advanced or metastatic colorectal cancer (CRC) who have received at least 2 prior lines of therapy and will explore clinical benefit according to human epidermal growth factor receptor 3 (HER3) tumor expression level in otherwise refractory tumors.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 2 |
Detailed Description
There will be 2 cohorts with enrollment in 2 parts. Participants will be treated on Day 1 of each 21-day cycle (every 3 weeks) with U3-1402 5.6 mg/kg intravenous (IV). The estimated treatment period is approximately 8 months and the follow-up period is approximately 4 months.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Cohort 1: HER3 High (IHC 3+, 2+) Cohort 1 participants will have high tumor expression levels of human epidermal receptor 3 (HER3) in a pre-treatment biopsy specimen. |
Drug: U3-1402
U3-1402 will be dosed at 5.6 mg/kg as an intravenous (IV) infusion administered on Day 1 of each 21-day cycle.
|
| Experimental: Cohort 2: HER3 Low/Negative (IHC 1+, 0) Cohort 2 participants will have low or negative tumor expression levels of human epidermal receptor 3 (HER3) expression levels in a pre-treatment biopsy specimen. |
Drug: U3-1402
U3-1402 will be dosed at 5.6 mg/kg as an intravenous (IV) infusion administered on Day 1 of each 21-day cycle.
|
Outcome Measures
Primary Outcome Measures
- Objective Response Rate (ORR) As Assessed By Blinded Independent Central Review (BICR) Following Administration of U3-1402 In Participants with Advanced or Metastatic Colorectal Cancer [From baseline up to disease progression by BICR, death, lost to follow up, or withdrawal of consent by subject (whichever occurs first), up to approximately 27 months]
ORR defined as the proportion of participants with a best overall response of confirmed complete response (CR) or partial response (PR) as assessed by blinded independent central review.
Secondary Outcome Measures
- Duration of Response (DOR) As Assessed by Blinded Independent Central Review (BICR) Following Administration of U3-1402 In Participants with Advanced or Metastatic Colorectal Cancer [From baseline up to disease progression by BICR, death, lost to follow up, or withdrawal of consent by subject (whichever occurs first), up to approximately 27 months]
DOR defined as the time from the first documented response (CR or PR) to the date of disease progression or death due to any cause.
- Objective Response Rate (ORR) As Assessed by Investigator Following Administration of U3-1402 In Participants with Advanced or Metastatic Colorectal Cancer [From baseline up to disease progression, death, lost to follow up, or withdrawal of consent by subject (whichever occurs first), up to approximately 27 months]
ORR defined as the proportion of participants with a best overall response (BOR) of confirmed complete response (CR) or partial response (PR) as assessed by Investigator.
- Duration of Response (DoR) As Assessed by Investigator Following Administration of U3-1402 In Participants with Advanced or Metastatic Colorectal Cancer [From baseline up to disease progression, death, lost to follow up, or withdrawal of consent by subject (whichever occurs first), up to approximately 27 months]
DoR defined as the time from the first documented response (complete response [CR] or partial response [PR]) to the date of disease progression or death due to any cause.
- Disease Control Rate (DCR) by Blinded Independent Central Review (BICR) and Investigator Following Administration of U3-1402 In Participants with Advanced or Metastatic Colorectal Cancer [From baseline up to disease progression by BICR, death, lost to follow up, or withdrawal of consent by subject (whichever occurs first), up to approximately 27 months]
DCR is defined as the proportion of participants who achieved a confirmed best overall response (BOR) of complete response (CR), partial response (PR), or stable disease (SD) as assessed by blinded independent central review or by the Investigator
- Time to Tumor Response (TTR) As Assessed by Blinded Independent Central Review (BICR) and Investigator Following Administration of U3-1402 In Participants with Advanced or Metastatic Colorectal Cancer [From baseline up to disease progression by BICR, death, lost to follow up, or withdrawal of consent by subject (whichever occurs first), up to approximately 27 months]
TTR defined as the time from the start of study treatment to the date of the first documentation of objective response (complete response [CR] or partial response [PR]) that is subsequently confirmed by Blinded Independent Central Review or by the Investigator
- Progression-free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) and Investigator Following Administration of U3-1402 In Participants with Advanced or Metastatic Colorectal Cancer [From baseline until disease progression by BICR, death, lost to follow up, or withdrawal of consent by subject (whichever occurs first), assessed up to 27 months]
PFS is defined as the time from the start of study treatment to the date of the first documentation of objective PD or death due to any cause, whichever is earlier
- Overall Survival (OS) Following Administration of U3-1402 In Participants with Advanced or Metastatic Colorectal Cancer [From baseline up to the date of death due to any cause or 27 months, whichever is earlier.]
OS defined as the time from the start of study treatment to the date of death due to any cause.
- Summary of Reported Treatment-emergent Adverse Events (TEAEs) and other safe parameters during the study [From baseline up to Day 40 post last dose, approximately 27 months]
Incidence of TEAEs, serious adverse events, adverse events of special interests (interstitial lung disease; and elevation of aminotransferases and total bilirubin), Eastern Cooperative Oncology Group performance status, vital sign measurements, standard clinical laboratory parameters will be assessed
- Proportion of Participants Who Are Anti-Drug Antibody (ADA)-Positive (Baseline and Post-Baseline) [From baseline up to 3 months post end of treatment, up to approximately 27 months]
The immunogenicity of U3-1402 will be assessed.
- Proportion of Participants Who Have Treatment-emergent ADA [From baseline up to 3 months post end of treatment, up to approximately 27 months]
The immunogenicity of U3-1402 will be assessed.
- Pharmacokinetic (PK) of Maximum Serum Concentration (Cmax) of analytes of U3-1402 Following Administration In Participants with Advanced or Metastatic Colorectal Cancer [At baseline (-8 hour to 0 hour), pre-infusion, and 15 minutes, 1 hour, 2 hour, 4 hour, and 8 hour post-infusion of Cycle 1 through Cycle 8 (each cycle is 21 days)]
Plasma concentrations at each time point and PK parameters Cmax of U3-1402 (ADC, total anti-HE antibody, and MAAA-1181a) will be assessed in the full PK sampling cohort
- Pharmacokinetic of Time to Reach Maximum Serum Concentration (Tmax) of analytes of U3-1402 Following Administration In Participants with Advanced or Metastatic Colorectal Cancer [At baseline (-8 hour to 0 hour), pre-infusion, and 15 minutes, 1 hour, 2 hour, 4 hour, and 8 hour post-infusion of Cycle 1 through Cycle 8 (each cycle is 21 days)]
Plasma concentrations at each time point and PK parameters Tmax of U3-1402 (ADC, total anti-HE antibody, and MAAA-1181a) will be assessed in the full PK sampling cohort
- Pharmacokinetic of Trough Serum Concentration (Ctrough) of analytes of U3-1402 Following Administration In Participants with Advanced or Metastatic Colorectal Cancer [At baseline (-8 hour to 0 hour), pre-infusion, and 15 minutes, 1 hour, 2 hour, 4 hour, and 8 hour post-infusion of Cycle 1 through Cycle 8 (each cycle is 21 days)]
Plasma concentrations at each time point and PK parameters Ctrough of U3-1402 (ADC, total anti-HE antibody, and MAAA-1181a) will be assessed in the full PK sampling cohort
- Pharmacokinetic of Area Under the Serum Concentration-Time Curve Up to Last Quantifiable Time (AUClast) and During Dosing Interval (AUCtau) of analytes of U3-1402 Following Administration In Participants with Advanced or Metastatic Colorectal Cancer [At baseline (-8 hour to 0 hour), pre-infusion, and 15 minutes, 1 hour, 2 hour, 4 hour, and 8 hour post-infusion of Cycle 1 through Cycle 8 (each cycle is 21 days)]
Plasma concentrations at each time point and PK parameters AUClast and AUCtau of U3-1402 (ADC, total anti-HE antibody, and MAAA-1181a) will be assessed in the full PK sampling cohort
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Participant has provided written informed consent prior to the start of any study specific procedures.
-
Participants ≥18 years (follow local regulatory requirements if the legal age of consent for study participation is >18 years old).
-
Pathological/histological confirmation of advanced or metastatic colon or rectal adenocarcinoma.
-
Must be resistant, refractory, or intolerant to at least 2 prior lines of systemic therapy, that must include all of the following agents:
-
Fluoropyrimidine
-
Irinotecan
-
Platinum agents (e.g, oxaliplatin)
-
An anti-epidermal growth factor receptor (EGFR) agent, if clinically indicated
-
An anti-VEGF agent, if clinically indicated (eg, bevacizumab)
-
An immune checkpoint inhibitor (eg, microsatellite instability-high [MSI-H] status)
-
A BRAF inhibitor, if clinically indicated (eg, BRAF V600E positive)
-
Has at least 1 measurable lesion confirmed by blinded independent central review (BICR) as per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1.
-
Willing to provide a required pre-treatment tumor biopsy and an additional archival tissue sample for the assessment of HER3 expression levels by immunohistochemistry and exploratory biomarkers, defined as:
-
Pre-treatment tumor biopsy. Participants may be exempted from the requirement to provide a pre-treatment tumor biopsy if archival tumor tissue was collected within 3 months of screening during or after treatment with the last prior cancer treatment and is of sufficient quantity (2 cores or 20 slides with adequate tumor tissue content).
-
An additional archival tissue sample collected greater than 3 months prior to screening must be available and of sufficient quantity, as defined above, at the time of screening. If an archival tissue sample (collected greater than 3 months prior to screening) is not available, a subject may be included provided the pre-treatment tumor biopsy is obtained and after discussion and agreement from Sponsor (Medical Monitor or designee).
-
Consent to provide on-treatment tumor biopsy. When at least 10 treatment tumor biopsies have been collected, the Sponsor will provide written notification of a change to the requirement.
-
Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1.
-
Life expectancy ≥3 months.
-
Has adequate bone marrow reserve and organ function at baseline based on local laboratory data defined as follows within 14 days prior to Cycle 1 Day 1:
-
Platelet count: ≥100,000/mm3 or ≥100 × 109/L (platelet transfusions are not allowed up to 14 days prior to Cycle 1 Day 1 to meet eligibility)
-
Hemoglobin: ≥9.0 g/dL (transfusion and/or growth factor support is allowed)
-
Absolute neutrophil count: ≥1500/mm3 or ≥1.5 × 109/L
-
Serum creatinine (SCr) OR creatinine clearance (CrCl): SCr ≤ 1.5 × upper limit of normal (ULN), OR CrCl ≥ 30 mL/min as calculated using the Cockcroft- Gault equation or measured CrCl; confirmation of CrCl is only required when creatinine is >1.5 × ULN
-
Alanine aminotransferase /aspartate aminotransferase: ≤3 × ULN (if liver metastases are present, ≤5 × ULN)
-
Total bilirubin: ≤1.5 × ULN if no liver metastases (<3 × ULN in the presence of documented Gilbert's syndrome [unconjugated hyperbilirubinemia] or liver metastases)
-
Serum albumin: ≥2.5 g/dL
-
Prothrombin time (PT) or PT-international normalized ratio (INR) and activated partial thromboplastin time (aPTT) / partial thromboplastin time (PTT): ≤1.5 × ULN except for subjects on coumarin- derivative anticoagulants or other similar anticoagulant therapy, who must have PT-INR within therapeutic range as deemed appropriate by the Investigator
Exclusion Criteria:
-
Any history of interstitial lung disease (including pulmonary fibrosis or radiation pneumonitis), has current interstitial lung disease (ILD), or is suspected to have such disease by imaging during screening.
-
Clinically severe pulmonary compromise (based on Investigator's assessment) resulting from intercurrent pulmonary illnesses including, but not limited to:
-
any underlying pulmonary disorder (e.g., pulmonary emboli, severe asthma, severe chronic obstructive pulmonary disease, restrictive lung disease, pleural effusion)
-
any autoimmune, connective tissue or inflammatory disorder with pulmonary involvement (eg, rheumatoid arthritis, Sjögren's syndrome, sarcoidosis)
-
OR prior complete pneumonectomy.
-
Is receiving chronic systemic corticosteroids dosed at >10 mg prednisone or equivalent anti-inflammatory activity or any form of immunosuppressive therapy prior to Cycle 1 Day 1. Participants who require use of bronchodilators, inhaled or topical steroids, or local steroid injections may be included in the study.
-
Evidence of leptomeningeal disease.
-
Evidence of clinically active spinal cord compression or brain metastases
-
Inadequate washout period prior to Cycle 1 Day 1 of U3-1402:
-
Whole brain radiation therapy <14 days or stereotactic brain radiation therapy <7 days;
-
Any cytotoxic chemotherapy, investigational agent or other anticancer drug(s) from a previous cancer treatment regimen or clinical study <14 days or 5 half-lives, whichever is longer;
-
Monoclonal antibodies other than immune checkpoint inhibitors, such as bevacizumab (anti-VEGF) and cetuximab (anti-EGFRs) <28 days;
-
Immune checkpoint inhibitor therapy <21 days;
-
Major surgery (excluding placement of vascular access) <4 weeks;
-
Radiotherapy treatment to >30% of the bone marrow or with a wide field of radiation <28 days or palliative radiation therapy <14 days;
-
Chloroquine/hydroxychloroquine ≤14 days.
-
Prior treatment with an anti-HER3 antibody and/or antibody drug conjugate (ADC) that consists of an exatecan derivative that is any topoisomerase I inhibitor (e.g, trastuzumab deruxtecan).
-
Has unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0 Grade ≤1 or baseline.
-
Had primary malignancies other than CRC within 3 years prior to Cycle 1 Day 1, except adequately resected non-melanoma skin cancer, curatively treated in-situ disease, or other solid tumors curatively treated.
-
Uncontrolled or significant cardiovascular disease prior to Cycle 1 Day 1.
-
Known Hepatitis B and/or Hepatitis C infection, such as those with serologic evidence of viral infection within 28 days of Cycle 1 Day 1.
- Participants with past or resolved hepatitis B virus (HBV) infection are eligible if:
-
Hepatitis B surface antigen (HBsAg) negative and hepatitis B core antibody (anti-HBc) positive; OR
-
HBsAg positive and HBV deoxyribonucleic acid (DNA) viral load is documented to be ≤2000 IU/mL in the absence of anti-viral therapy and during the previous 12 weeks prior to the viral load evaluation with normal transaminases values (in the absence of liver metastasis); OR
-
HBsAg positive and HBV DNA viral load is documented to be ≤2000 IU/mL in the absence of anti-viral therapy and during the previous 12 weeks prior to the viral load evaluation for participants with liver metastasis and abnormal transaminases with a result of AST/ALT <3 × ULN.
- Participants with a history of hepatitis C infection will be eligible for enrollment only if the viral load according to local standards of detection is documented to be below the level of detection in the absence of anti-viral therapy during the previous 12 weeks (ie, sustained viral response according to the local product label but no less than 12 weeks, whichever is longer).
-
Participant with any human immunodeficiency virus (HIV) infection.
-
Any evidence of severe or uncontrolled systemic diseases (including active bleeding diatheses, active infection), psychiatric illness/social situations, geographical factors, substance abuse, or other factors which in the Investigator's opinion makes it undesirable for the participant to participate in the study or which would jeopardize compliance with the protocol. Screening for chronic conditions is not required.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Highlands Oncology | Fayetteville | Arkansas | United States | 72703 |
| 2 | City of Hope Comprehensive Cancer Center | Duarte | California | United States | 91010 |
| 3 | University of Colorado Hospital | Aurora | Colorado | United States | 80045 |
| 4 | Moffitt Cancer Center | Tampa | Florida | United States | 33612 |
| 5 | Emory University | Atlanta | Georgia | United States | 30322 |
| 6 | Northwestern Medical Faculty Foundation NMFF Hematology Oncology | Chicago | Illinois | United States | 60611 |
| 7 | John Hopkins Sidney Kimmel Comprehensive Cancer Center | Baltimore | Maryland | United States | 21287 |
| 8 | Henry Ford Health System | Detroit | Michigan | United States | 48202 |
| 9 | Mayo Clinic | Rochester | Minnesota | United States | 55902 |
| 10 | Washington University | Saint Louis | Missouri | United States | 63110 |
| 11 | Nebraska Cancer Specialists | Omaha | Nebraska | United States | 68130 |
| 12 | Rutgers Cancer Institute of New Jersey | New Brunswick | New Jersey | United States | 08901 |
| 13 | Memorial Sloan Kettering Cancer Center | New York | New York | United States | 10065 |
| 14 | Duke University Medical Center | Durham | North Carolina | United States | 27710 |
| 15 | West Cancer Center | Germantown | Tennessee | United States | 38138 |
| 16 | Sarah Cannon | Nashville | Tennessee | United States | 37203 |
| 17 | Mary Crowley Cancer Research | Dallas | Texas | United States | 75230 |
| 18 | University of Texas Southwestern Medical Center | Dallas | Texas | United States | 75390 |
| 19 | MD Anderson Cancer Center University of Texas | Houston | Texas | United States | 77030 |
| 20 | Utah Cancer Specialists | Salt Lake City | Utah | United States | 84106 |
| 21 | Virgina Cancer Specialists | Fairfax | Virginia | United States | 22031 |
| 22 | UZ Antwerpen | Edegem | Belgium | 2650 | |
| 23 | UZ Leuven | Leuven | Belgium | 3000 | |
| 24 | Centre Georges-Franois Leclerc | Dijon | France | 21000 | |
| 25 | CHU Nantes | Nantes | France | 44000 | |
| 26 | Hospital St Antoine | Paris | France | 75012 | |
| 27 | Asst Grande Ospedale Metropolitano Niguarda | Milano | Italy | 20162 | |
| 28 | Aichi Cancer Center Hospital | Nagoya-shi | Nagoya-shi, Aichi-ken | Japan | 464-8681 |
| 29 | National Hospital Organization - Osaka National Hospital (ONH) | Osaka-shi | Osaka-shi, Osaka-fu | Japan | 540-0006 |
| 30 | Kindai University Hospital | Osaka | Osakasayama Shi | Japan | 589-8511 |
| 31 | National Cancer Center Hospital East | Chiba | Japan | 277-0023 | |
| 32 | The Cancer Institute Hospital Of JFCR | Tokyo | Japan | 135-8550 | |
| 33 | Szpital Kliniczny Przemienienia Panskiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu | Ostrów Wielkopolski | Poznan | Poland | 60-569 |
| 34 | Szpital Kliniczny Przemienienia Pańskiego.University Hospital, Chemotherapy Department | Poznań | Poland | ||
| 35 | M Sklodowska Curie Memorial Cancer Center | Warszawa | Poland | 02-034 | |
| 36 | M Sklodowska Curie Memorial Cancer Center | Warszawa | Poland | ||
| 37 | Hospital del Mar - Institut Hospital del Mar d'Investigacions Mediques IMIM | Barcelona | Spain | 08003 | |
| 38 | VHIO Valle de Hebron Instituto de Oncologia | Barcelona | Spain | 08035 | |
| 39 | Hospital Universitario La Paz | Madrid | Spain | 28046 | |
| 40 | Hospital Universitario HM Sanchinarro, CIOCC | Madrid | Spain | 28050 | |
| 41 | Consorci Corporació Sanitària Parc Taulí de Sabadell | Sabadell | Spain | 08208 | |
| 42 | Hospital Universitario Virgen del Rocio | Sevilla | Spain | 41013 | |
| 43 | Royal Marsden Hospital NHS | London | United Kingdom | SW3 6JJ | |
| 44 | Sarah Cannon Research Institute UK | London | United Kingdom | W1G 6AD | |
| 45 | Royal Marsden Hospital NHS | London | United Kingdom | ||
| 46 | Sarah Cannon | London | United Kingdom |
Sponsors and Collaborators
- Daiichi Sankyo, Inc.
Investigators
- Study Director: Global Clinical Leader, Daiichi Sankyo, Inc.
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- U31402-A-U202
- 2019-004418-32